TT
Transcend Therapeutics
OrganizationHeard in 5 episodes across 2 shows since Jul 2026
Transcend Therapeutics is a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric disorders. Its lead investigational candidate, TSND-201 (methylone), is being developed for post-traumatic stress disorder (PTSD) and has received FDA Breakthrough Therapy designation.
Episodes
5
across 2 shows
First heard
Jul 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
2
2
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 1 |
| Aug 2026 | 0 |
| Sep 2026 | 2 |
| Oct 2026 | 0 |
| Nov 2026 | 2 |
Email alert
Email me when Transcend Therapeutics comes up on a podcast
One email a week at most, with the new episodes that mention Transcend Therapeutics. Free, no account needed, unsubscribe in one click.
Episodes
5 episodes featuring Transcend Therapeutics, newest first
- Nov 11, 2026
Ferriss turns a live Q&A into a case for deliberate experimentationThe Tim Ferriss ShowNov 11, 2026 - Nov 5, 2026
Solvonis expands ketamine patent into behavioral addictionsThe Sunday RoastNov 5, 2026 - Sep 24, 2026
Kevin Ryan bets on durable trends over startup hypeThe Tim Ferriss ShowSep 24, 2026 - Sep 18, 2026
Australia’s psychedelic breakthrough offers advocates a regulatory playbookThe Tim Ferriss ShowSep 18, 2026 - Jul 22, 2026
Andrew Huberman outlines the science of high-intensity training and peptidesThe Tim Ferriss ShowJul 22, 2026